



(51) International Patent Classification:

C07D 487/04 (2006.01) C07F 9/142 (2006.01)

C07D 471/04 (2006.01) A61P 37/00 (2006.01)

C07D 491/04 (2006.01) A61K 31/519 (2006.01)

(21) International Application Number:

PCT/EP2023/078739

(22) International Filing Date:

17 October 2023 (17.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/379,950 18 October 2022 (18.10.2022) US

(71) Applicant: **GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED** [GB/GB]; GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB).

(72) Inventors: **BOTYANSZKI, Janos**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **CHARNLEY, Adam**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **DONG, Xiaoyang**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **HUMPHREYS, Philip**; GSK, Gunnels Wood Road, Stevenage SG1 2NY (GB). **KING, Bryan**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **MARCUS, Kimberly**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **NEWLANDER, Kenneth**; c/o GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **PERO, Joseph**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US).

(72) Inventor: **RAHMAN, Attiq** (deceased).

(72) Inventors: **REIF, Alexander**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **WIGGALL, Kenneth**; c/o GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **ZHANG, Daohua**; GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426 (US). **RAMANJULU, Joshi**; 1250 South Collegeville Road, Collegeville, PA 19426 (US).

(74) Agent: **AHERN, Jenna**; GSK, (Global Patents CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS

(57) Abstract: The present invention relates to compounds, compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE) and lupus nephritis.

WO 2024/083773 A1